CAR-NK Cell Therapy for Advanced Ovarian Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to target and fight ovarian cancer that has returned or stopped responding to standard treatments. The therapy uses cells from your own body that have been modified in the lab to recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have epithelial ovarian, fallopian tube, or primary peritoneal cancer that has come back or stopped responding after at least 2 prior treatment regimens
- Your cancer can be measured on imaging scans (RECIST v1.1 criteria)
- You are in good enough health to tolerate the treatment (ECOG performance status 0-1, meaning you can carry out normal daily activities)
- Your tumor tissue shows specific markers (antigens) that the CAR-NK cells can recognize and attack
- Your heart, liver, kidneys, and blood counts are healthy enough per blood tests
- You are not pregnant, not breastfeeding, and agree to use effective birth control after the cell infusion
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
This trial tests a new treatment called CAR-T cells that target a protein called B7H3 found on cancer cells. It is for people with a specific type of ovarian, peritoneal, or fallopian tube cancer that has not responded well to platinum chemotherapy or has come back quickly.
This early-phase trial tests a lab-made immune cell treatment for advanced solid tumors that show specific targets (including Claudin 6, GPC3, Mesothelin, or AXL). It may help the immune system better recognize and kill tumor cells, but eligibility depends on test results and your overall health.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.